9 Feb
2021

Five IP takeaways from Jazz Pharmaceuticals’ $7 billion medical cannabis buyout

The agreement to purchase GW Pharmaceuticals is not just big news for life sciences M&A, but has several points of interest for IP professionals and dealmakers

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth